Physician profile
Brent Alan Savelli
NPI 1306878251
$5,415.82
in general payments reported to CMS, 2019-2025
47 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $892 · 2021: $736 · 2022: $692 · 2023: $943 · 2024: $503 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.73 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,301.72 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $596.09 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $459.39 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $237.57 | 2019-2023 | |
| Glaxosmithkline, LLC. | $236.95 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $222.95 | 2019-2023 | Xarelto |
| Allergan, INC. | $222.90 | 2019-2020 | |
| Abbvie INC. | $180.99 | 2019-2025 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $163.50 | 2020-2023 | Veozah |
| Amarin Pharma, INC. | $142.10 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.79 | 2019-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $118.48 | 2022-2023 | |
| Antares Pharma, INC. | $113.25 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Biogen, INC. | $110.13 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $94.72 | 2019-2023 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.77 | 2020-2023 | Jardiance |
| Sunovion Pharmaceuticals INC. | $78.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $78.10 | 2019-2020 | |
| Radius Health, INC. | $72.06 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $68.46 | 2023-2025 | Quviviq, Quviviq |
| Abbott Laboratories | $60.36 | 2021-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $55.34 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $48.14 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $44.22 | 2024-2025 | Zenpep |
| Ucb, INC. | $43.24 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $40.57 | 2021-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $37.75 | 2020 | |
| Merck Sharp & Dohme LLC | $33.28 | 2020-2022 | |
| Almatica Pharma LLC | $31.62 | 2021-2024 | Loreev Xr, Teriparatide |
| Halozyme INC | $28.51 | 2023 | |
| Ardelyx, INC. | $24.49 | 2024 | Ibsrela |
| Alfasigma USA, INC. | $21.61 | 2020 | |
| Sumitomo Pharma America, INC. | $20.20 | 2023 | Gemtesa |
| Horizon Therapeutics Plc | $19.76 | 2023 | Krystexxa |
| Dexcom, INC. | $17.51 | 2022 | |
| Evoke Pharma, INC. | $17.31 | 2023 | Gimoti |
| Phathom Pharmaceuticals, INC. | $16.36 | 2025 | Voquezna |
| Eisai INC. | $16.26 | 2020 | |
| Medline Industries LP | $16.20 | 2023 | |
| Axsome Therapeutics, INC. | $16.11 | 2025 | Auvelity |
| Adlon Therapeutics L.P. | $15.78 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.90 | 2023 | Nuzyra |
| Exact Sciences Corporation | $14.72 | 2025 | The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $14.01 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.19 | 2019 | |
| Linus Health, INC. | $10.31 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Savelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.